Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report

• Principais autores: Jowan Al-Nusair MD (Autor), Reesha Bodiwala DO (Autor), Kemnasom Nwanwene MD (Autor), Mahmoud Abdallah (Autor), Mohamed Alshal MD (Autor), Toni Pacioles MD (Autor)
• Formato: Livro
• Publicado em: SAGE Publishing, 2024-11-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Lung cancer, a leading cause of cancer mortality, often involves epidermal growth factor receptor (EGFR) mutations, common in 17% of Caucasian and 40% of Asian non-small-cell lung cancer (NSCLC) patients. While the exon 19 deletion and L858R mutation are prevalent, rare variants like L833V/H835L are...